Atea Pharmaceuticals
AVIR
111 hedge funds and large institutions have $203M invested in Atea Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 43 reducing their positions, and 12 closing their positions.
32% more capital invested
Capital invested by funds: $154M → $203M (+$49.3M)
5.96% more ownership
Funds ownership: 67% → 72.96% (+6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
3% less funds holding
Funds holding: 115 → 111 (-4)
30% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.3M |
| 2 |
JP Morgan Chase
New York
|
+$2.32M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.06M |
| 4 |
Two Sigma Investments
New York
|
+$871K |
| 5 |
Two Sigma Advisers
New York
|
+$837K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.53M |
| 2 |
NM
Newtyn Management
New York
|
-$1.43M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.13M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$953K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$565K |
AVIR Hedge Fund Activity: Q4 2025 in Review
111 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q4 2025, worth a combined $203M — up 32% from $154M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of AVIR and 11 opened new positions — a net loss of 1 holder — while 43 trimmed existing stakes and 30 added.
The largest buyer was Fidelity Investments, adding an estimated $12.3M. The largest seller was Vanguard Group, cutting an estimated $1.53M.
- 111 institutional investors held Atea Pharmaceuticals (AVIR) as of Q4 2025, down from 115 in Q3 2025.
- Funds reported $203M of Atea Pharmaceuticals stock for Q4 2025, up 32% quarter-over-quarter.
- 11 funds opened new Atea Pharmaceuticals positions in Q4 2025 and 12 closed out, a net change of -1 holder.
- The largest Atea Pharmaceuticals buyer in Q4 2025 was Fidelity Investments, an estimated $12.3M added.
- The largest Atea Pharmaceuticals seller in Q4 2025 was Vanguard Group, an estimated $1.53M sold.
Based on aggregated 13F filings for Q4 2025.